RxSight shares fall 38% after Q2 revenue decline and guidance cut.

• RxSight investigation for securities law violations • Misleading statements and undisclosed information suspected • Q2 2025 financial results revealed declines in sales and revenue • Full-year guidance lowered due to "adoption challenges" • Shares fell by 38% on July 9, 2025 • DJS Law Group investigating on behalf of investors.

The DJS Law Group has announced it is investigating claims on behalf of investors of RxSight, Inc. (NASDAQ: RXST) for potential violations of securities laws [1]. The investigation focuses on whether the company issued misleading statements or failed to disclose pertinent information to investors.

On July 9, 2025, RxSight reported its financial results for the second quarter of 2025, revealing significant declines in key metrics. Sales of Light Delivery Devices (LDD) and total revenue across the organization both decreased. Additionally, the company lowered its full-year financial performance guidance, citing "adoption challenges" that have caused an "LDD stall" [2].

Following the announcement, shares of RxSight fell by just under 38% on the same day. If you are a shareholder who suffered a loss, the DJS Law Group is inviting you to participate in the investigation [1].

The DJS Law Group specializes in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. They have a strong track record of representing some of the largest and most sophisticated hedge funds and alternative asset managers in the world [1].

References:
[1] https://www.prnewswire.com/news-releases/rxsight-inc-investigated-for-securities-fraud-violations---contact-the-djs-law-group-to-discuss-your-rights--rxst-302531936.html
[2] https://www.marketscreener.com/news/rxsight-inc-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-yo-ce7c51dfde8ffe20